It may help other readers though.
I note the half yearly produced 3 weeks after the quarterly said page 4:
"The Company continues to see wet concentration plant (“WCP”) availability consistently above target of 90% and
this, combined with higher heavy mineral ore grades (higher than in 1H 2020), supported HMC production of
187,000 tonnes for the half year, putting the Company in a strong position to achieve HMC production guidance
for CY2021 of 300,000 to 330,000 tonnes."
Note it says achieve production guidance which is a range. It does not say exceed guidance. I am more interested in 2022.
The half yearly also says page 5:
" In addition, further work is being undertaken immediately to the south of existing reserves
at Boonanarring (in blocks D, E and F) to assess the potential for additional Boonanarring mine life given stronger
mineral sands commodity prices."
I take that to mean they would mine lower grade areas in 2022 and delay Atlas, as higher pricing may make lower grades economic.
As you say we disagree. Let us see what happens.
- Forums
- ASX - By Stock
- IMA
- Ann: Half Year Accounts
Ann: Half Year Accounts, page-39
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMA (ASX) to my watchlist
|
|||||
Last
7.4¢ |
Change
-0.001(0.68%) |
Mkt cap ! $82.54M |
Open | High | Low | Value | Volume |
7.4¢ | 7.4¢ | 7.4¢ | $15.79K | 213.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 156173 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.4¢ | 21003 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 156173 | 0.073 |
4 | 74000 | 0.072 |
1 | 55000 | 0.071 |
3 | 171220 | 0.070 |
1 | 10000 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.074 | 21003 | 1 |
0.075 | 20000 | 1 |
0.078 | 49297 | 1 |
0.079 | 55889 | 2 |
0.080 | 35495 | 1 |
Last trade - 15.56pm 15/07/2024 (20 minute delay) ? |
Featured News
IMA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online